Table 3.

The EC₅₀ values of PVE30 at different virus infectious cycles evaluated by the plaque reduction assay (Unit: μg/mL)

	HSV-1/KOS	HSV-2/G
Pre-infection	> 100	> 100
Attachment	4.53 ± 0.21***	4.61 ± 0.40***
Penetration	27.86 ± 2.58*	22.77 ± 2.50
Post-infection	33.36 ± 0.77	26.61 ± 0.86

Antiviral effects were evaluated by a plaque reduction assay to determine the 50% effective concentration (EC₅₀)

Values represent the mean ± S.D. from three independent experiments with each treatment performed in duplicate

***P < 0.001, *P < 0.05, vs. post-infection group